Efficacy and safety of trastuzumab deruxtecan therapy

Efficacy and safety of trastuzumab deruxtecan therapy

Blog Article

Antibody-drug conjugates (ADCs) are a new generation of drugs that currently represent one of the most effective treatment options for cancer.ADCs target a specific target (antigen) that is selectively expressed on a tumour cell.Binding of ADCs to a tumour cell results in targeted intracellular delivery of cytotoxic drugs which causes cell death.An ADC called trastuzumab deruxtecan (T-DXd) has shown remarkable efficacy in several clinical trials called DESTINY.Initial data were available coleman 125 ut parts for patients with metastatic HER2-positive breast cancer, followed by data on other HER2-positive solid cancers and breast cancer with low HER2 expression.

In this article, we present the first data on the efficacy and safety of T-DXd in Slovenia.We conducted a retrospective study of patients treated with T-DXd at the Institute of Oncology Ljubljana from November 2021 lego.bonsai tree to April 2024.We observed good responses to treatment (objective response 59% in HER2-positive breast cancer, 38% in other HER2-positive solid cancers and 33% in breast cancer with low HER2 expression).After a short median follow-up of 8.8 (95% CI 0.

8-33.3) months, real world progression-free survival (rwPFS) was 13 months in HER2-positive breast cancer, 5.8 months in HER2-low breast cancer, and 7.7 months in other HER2 positive or HER2-mutated solid cancers.The safety profile was consistent with that reported in the registration studies, with the exception of pneumonitis, which was reported in a much lower percentage (only 1%).

We can conclude that the response rate to T-DXd is high despite the late treatment lines and the heterogeneous population, while rwPFS assessment is unreliable due to the short observation period.